PTEN and glioblastoma: Patient selection and biomarkers emerge as key topics, with Dono et al[62] investigating the influence of Phosphatase and Tensin Homolog Deleted (PTEN) mutation on the response to TTFields therapy in recurrent Glioblastoma Rgbm.